ID: MRFR/HC/8901-CR | December 2020 | Region: Global | 193 pages
Global Compounding Chemotherapy Market is expected to register a CAGR of 6.04% during the assessment period of 2020 to 2027, to reach USD 635.58 Million by 2027.
Many technical advances and cutting-edge strategies have allowed pharmacies to respond to the needs of clinicians and boost the growth of the global compounding chemotherapy market. Furthermore, the increasing opioid scarcity s is expected to increase demand globally for compounding chemotherapy. In addition, multiple advantages, including easy to use medicines, allowing alternative dosage types to access expired medicines and making medicines allergen safe, are expected to fuel the demand during the forecast period. In addition, hospitals and other healthcare providers are allowing customers to purchase medications that are compounded.
Global Compounding Chemotherapy Market, by Dose, 2019 (%)
Source: MRFR Analysis
Global Compounding Chemotherapy Market is segmented, based on Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, and Application.
Global Compounding Chemotherapy Market based on the dose has been segmented into chemotherapeutic and non-chemotherapeutics. Chemotherapeutic dominated the market in 2019. The projected growth of the market over the forecast period is attributed to increased incidence of cancer, rising expenditure on medicine & science and reimbursements, and increased health benefits. The global compounding chemotherapy market, by compounding type, has been segmented into pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM), and pharmaceutical dosage alteration (PDA). The PDA segment is expected to witness a rapid growth rate during the forecast period. As composite procedures in the pediatric and geriatric patient pools are generally followed, problems in swallowing and medicine handling daily contribute to higher adoption of PDA compounding practices.
The global compounding chemotherapy market, by delivery method, has been segmented into gravimetric automated compounding device (weight-based) and volumetric automated compounding device (volume-based). The gravimetric automated compounding device (weight-based) segment dominated the market in 2019. In the development of gravimetric automated composites, the adoption of chemotherapy and personalized medicines is increased. The global compounding chemotherapy market, by sterility, has been segmented into sterile and non-sterile. The sterile segment held the largest share of 56.0% in 2019. Chemotherapy based on sterile substances is meant as infusions and injections. Therefore, in this process of compounding, the risk of bacterial infection is high. The market for the global compounding chemotherapy market, by technology, is bifurcated into with robotic arms and without robotic arms. The with robotic arm held the largest share with a CAGR of 6.46% in 2019. The market for the global compounding chemotherapy market, by compounder type, is bifurcated into Pharmoduct, Equashield Pro, Medimix, Integra, and others. The pharmoduct held the largest share with a CAGR of 7.84% in 2019. Pharmoduct is an electronic and proprietary method used in the sterile processing of oncological, chemical, and biologic compounding pharmaceutical products. The market for the global compounding chemotherapy market, by application, is bifurcated into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, respiratory/lung cancer, and others.
Americas Compounding Chemotherapy Market Share, by Country, 2019 (%)
Source: MRFR Analysis
Global Compounding Chemotherapy Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. This is attributed to an increase in cancer patients, a rise in health care rates, and the demand for treatment with chemotherapy in the area.
The European compounding chemotherapy market has been divided into Western Europe and Eastern Europe. The Western Europe compounding chemotherapy market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. During the projected period, Europe is likely to follow America in terms of revenue due to government-based research program aimed at curing the rising number of cancer cases and an increased health spending push the growth of the regional chemotherapy market.
The compounding chemotherapy market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The highest growth opportunity for Asia-Pacific is anticipated in the projected period since this strong growth is primarily attributed to the expanded research and development support for the healthcare sector from developing countries such as China and India.
The Middle East & Africa Compounding Chemotherapy market is segmented into the Middle East and Africa. Due to fewer trends and low revenues, enhanced chemotherapy therapies are projected to improve. With a rapidly aging population, cancer care in this area is expected to increase.
The Prominent Players in the Global Compounding Chemotherapy Market are Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni.
Some of the key strategies followed by players operating in the global compounding chemotherapy market were FDA approvals, joint ventures, acquisitions, expansions, and collaborations.
Global Compounding Chemotherapy Market, By Dose
Global Compounding Chemotherapy Market, By Compounding Type
Global Compounding Chemotherapy Market, By Delivery Method
Global Compounding Chemotherapy Market, By Sterility
Global Compounding Chemotherapy Market, By Technology
Global Compounding Chemotherapy Market, By Compounder Type
Global Compounding Chemotherapy Market, By Region
Available Additional Customizations
|Market Size||635.58 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors and Trends|
|Segments Covered||Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, and Application|
|Geographies Covered||North America, Europe, Asia-Pacific and Rest of the World (RoW)|
|Key Vendors||Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni.|
|Key Market Opportunities||Opioid scarcity|
|Key Market Drivers||
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.